GlassScriptPhysician profile
Savannah Mckenzie
NPI 1578088431
$3,932.44
in general payments reported to CMS, 2019-2025
20 companies · $964 in 2025
The $964 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $334 · 2023: $1,124 · 2024: $1,164 · 2025: $964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.60 |
| Education | $369.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $672.26 | 2021-2025 | |
| Janssen Biotech, INC. | $603.40 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $592.23 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $322.50 | 2021-2025 | |
| Ucb, INC. | $212.76 | 2022-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $205.37 | 2021-2025 | Absorica Ld, Winlevi |
| Journey Medical Corporation | $205.09 | 2021-2023 | |
| Leo Pharma INC. | $184.98 | 2023-2025 | Adbry |
| Incyte Corporation | $182.22 | 2023-2024 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $149.36 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $134.68 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $128.26 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Strata Skin Sciences, INC. | $87.69 | 2023-2025 | Xtrac |
| Amgen INC. | $84.18 | 2022-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.94 | 2023-2024 | Spevigo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.63 | 2023 | Duobrii, Arazlo, Jublia |
| Galderma Laboratories, L.P. | $27.04 | 2024-2025 | Nemluvio |
| Pfizer INC. | $25.80 | 2021-2024 | |
| Organon LLC | $19.46 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $17.59 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savannah Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.